Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) generates news at the intersection of cell therapy, oncology and metabolic disease research. Company announcements and SEC-referenced disclosures describe a business that has combined T-cell receptor (TCR) cell therapy programs for solid tumors with a preclinical-stage obesity and metabolic health drug development effort built around a small molecule candidate.
News items for TCRT commonly cover clinical and translational updates from its TCR-T Library Phase 1/2 trial at The University of Texas MD Anderson Cancer Center, including disease control rates, objective responses in metastatic, refractory solid tumors, and safety and tolerability findings for its Sleeping Beauty-engineered TCR-T cells. Releases also highlight the capabilities of the hunTR ae TCR discovery platform, which the company reports has identified proprietary TCRs targeting driver mutations such as KRAS and TP53.
Investors following TCRT news will also see coverage of Alaunos strategic reprioritization and corporate actions. The company has publicly discussed winding down its TCR-T clinical trial, refocusing on the hunTR ae platform, and exploring strategic alternatives that may include acquisitions, mergers, reverse mergers, asset sales, partnerships or capital raises. Financial results releases detail research and development spending, restructuring costs, workforce reductions and cash runway expectations as the company adjusts its operations.
In addition, Alaunos issues news on capital markets activity, such as registered direct offerings of common stock and pre-funded warrants under a shelf registration statement, private offerings of convertible preferred stock, and equity purchase agreements registered on Form S-1. Governance and listing-related updates, including board changes, executive transitions and Nasdaq compliance notices and resolutions, also appear in the news flow. For readers tracking TCRT, this page aggregates these operational, clinical, financial and regulatory developments in one place.
Valion Bio (Nasdaq: VBIO) appointed Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, effective May 4, 2026. Ms. Lackey brings nearly two decades of combined scientific, IP, clinical-stage, and Nasdaq public company experience.
Her background includes senior legal roles at Alaunos Therapeutics and Kuur Therapeutics, patent litigation experience at Winston & Strawn and Howrey, and early research roles at UT Health Science Center and MD Anderson. The hire is positioned to support Entolimod's FDA Animal Rule pathway, an ongoing capital raise, and scaling of the Velocity Bioworks CDMO in San Antonio.
Alaunos Therapeutics (Nasdaq: TCRT) reported positive non-GLP preclinical DIO mouse data for ALN1003, an oral non-hormonal obesity candidate. Key findings: dose-dependent weight loss (peak -12.9% at Day 34), marked liver-weight reductions (up to -55%), improved glucose (197 vs 320 mg/dL) and lower total cholesterol.
Company plans further preclinical, CMC, formulation work, IND-enabling studies and next-generation chemistry; cash was ~$1.9M as of Sept 30, 2025, with runway into Q2 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.